FGFR4 and neoplasm: Although it has been reported that pharmacologically use of FGF15/19 leads to liver cell growth and neoplasia [128], NGM282, a full FGFR4 agonist, due to its inability to activate STAT3 pathway, it lacks tumor-promoting activity in mice [126, 132].